Start here if you're new
what it is
Enovis sells orthopedic implants, braces, and rehab gear that doctors use to fix joints and keep patients moving.
how it gets paid
Last year Enovis made $2.2B in revenue. Bracing & supports was the main engine at $0.62B, or 28% of sales.
why it's growing
Revenue grew 6.7% last year. We believe the latter segment got a boost from good demand for both hip/knee and extremities goods.
what just happened
Enovis posted $0.95 EPS versus a $0.85 estimate, but the cleaner story is still revenue scale over margin quality.
At a glance
B balance sheet — gets the job done, barely
7.1x trailing p/e — the market's not buying it — or you found a deal
7.0% return on capital — nothing to write home about
xvary composite: 49/100 — below average
$4.60 fy2029 eps est
What they do
Enovis sells orthopedic implants, braces, and rehab gear that doctors use to fix joints and keep patients moving.
This business sits where a surgeon's habit meets a patient's pain. If your doctor already trusts an implant system or a brace line, switching is messy and risky. That habit helps Enovis turn $2.2 billion of annual revenue into a platform that spans prevention, surgery, and recovery.
How they make money
$2.2B
annual revenue · their business grew +6.7% last year
Bracing & supports
$0.62B
+6.7%
Recovery sciences
$0.26B
+6.7%
Hip reconstruction
$0.44B
+5.0%
Knee reconstruction
$0.40B
+5.0%
Extremities & foot/ankle
$0.48B
+5.0%
The products that matter
orthopedic bracing and recovery products
Bracing & Recovery
part of a $2.2B revenue base
source commentary points to firm demand here, and the company still delivered $2.2B of total revenue last year. this is the steady side of the story.
core demand
hip, knee, and extremity implants
Surgical Implants
supported a $549M quarter
reconstructive demand was cited as a tailwind in the latest quarter. the page does not disclose segment revenue, so you should treat this as a real driver with thin disclosed detail.
reconstructive
the combined orthopedic platform
Enovis platform
9.0% net margin
the entire platform turns $2.2B of revenue into a 9.0% net margin. profitable, yes. structurally elite, no.
execution bet
Key numbers
7.1x
trailing p/e
You are paying 7.1 times earnings for a medtech name the market thinks is messy. Cheap is the whole argument here.
$37
18-month target
That target is 63% above $22.72. The gap says expectations are low and the setup is very sensitive to execution.
$1.3B
long-term debt
Debt equals 51% of capital. Translation: lenders get a seat at your table whether you like it or not.
50.0%
operating margin
This is the quiet part out loud. The company sells products at a 59.5% gross margin and still loses money after operating costs.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 45 / 100
- long-term debt $1.3B (51% of capital)
- net profit margin 9.4% — keeps 9 cents of every dollar in revenue
- return on equity 9% — $0.09 profit for every $1 investors have put in
B — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in ENOV 3 years ago → it's now worth $3,640.
The index would have given you $14,770.
source: institutional data · total return
What just happened
beat estimates
Enovis posted $0.95 EPS versus a $0.85 estimate, but the cleaner story is still revenue scale over margin quality.
Quarterly revenue reached $1.7 billion, up 205% vs. prior year, while gross margin was 59.5%. Recent commentary pointed to firm bracing demand and good demand in hip, knee, and extremities.
$1.7B
revenue
$0.95
eps
59.5%
gross margin
the number that mattered
The 59.5% gross margin matters most because it shows the products have pricing power, even while operating costs still wreck the income statement.
-
enovis corporation probably closed out 2025 with mixed results.
-
we think fourth-quarter sales increased 5% compared to the previous-year tally.the advance was likely driven by solid gains from both the prevention & recovery and reconstructive segments.
-
the former division probably benefited from firm global demand for bracing products.
-
we believe the latter segment got a boost from good demand for both hip/knee and extremities goods.
-
however, share earnings were likely flattish compared to the prior-year figure.we think the bottom line was hurt by the negative impact of tariffs, as management stated that these costs have begun to work their way through inventory.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is debt-heavy orthopedic execution — Enovis has $1.3B of long-term debt, and this business only earns 6.0% on capital.
med
balance sheet pressure
$1.3B of long-term debt equals 51% of capital. That is manageable when demand is steady and margins hold. It gets uncomfortable fast if operating results slip.
With leverage already elevated, Enovis has less room to absorb a bad year than the valuation makes it look.
med
tariffs and cost inflation in inventory
management commentary says tariff costs have started moving through inventory. On a 9.0% net margin, that is not background noise.
If input costs keep leaking through, the margin line takes the hit before revenue does.
med
orthopedic demand slowdown
the revenue case leans on healthy bracing demand and reconstructive procedure volumes. If hospitals, surgeons, or patients pull back, the whole $2.2B revenue base feels it.
This is not a diversified conglomerate. A procedure slowdown hits the core business, not a side segment.
med
earnings quality and data noise
a page showing -$9.99 of quarterly EPS and $3.75 of full-year EPS in the same breath is a reminder that the earnings story needs clarity. Cheap multiples do not help if investors do not trust the inputs.
When the numbers look messy, the stock stays cheap longer than value screens expect.
$1.3B of debt, 51% leverage to capital, and a 9.0% net margin mean Enovis does not need a collapse to feel pressure — it only needs costs to stay elevated while demand cools.
source: institutional data · regulatory filings · risk analysis
Pay attention to
earnings
the next quarterly margin print
revenue already looks steadier than EPS. the next report needs to show whether tariff costs are easing or still bleeding through inventory.
metric
return on capital above 6.0%
that is the cleanest test for whether this business is getting more efficient or just staying cheap.
risk
debt as a percent of capital
51% is already meaningful. you want to see that number move down, not become the permanent shape of the balance sheet.
trend
procedure demand in bracing and reconstructive
the latest commentary says both were supportive. if one stalls, the market will notice before management finishes the sentence.
Analyst rankings
short-term outlook
average
momentum score 3. in human-speak, analysts do not see a strong short-term edge here.
risk profile
average
stability score 3. this is middle-of-the-road risk, not a bunker and not a rollercoaster.
chart momentum
average
technical score 3. the chart is not doing the bull case any favors yet.
source: institutional data
Institutional activity
143 buyers vs. 159 sellers in 3q2025. total institutional holdings: 66.1M shares.
source: institutional data
Price targets
3-5 year target range
$19
$55
$23
current price
$37
target midpoint · +63% from current · 3-5yr high: $65 (+185% · 30% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive